Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Cancer Communications ◽

10.1002/cac2.12179 ◽

2021 ◽

Author(s):

Yuankai Shi ◽

Kaijian Lei ◽

Yuming Jia ◽

Bingqiang Ni ◽

Zhiyong He ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Chinese Patients ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

Double Blinded ◽

First Line Treatment

Download Full-text

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.479 ◽

2021 ◽

Vol 32 (1) ◽

pp. 85-96 ◽

Cited By ~ 1

Author(s):

M. Shi ◽

A. Gu ◽

H. Tu ◽

C. Huang ◽

H. Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

BMC Cancer ◽

10.1186/s12885-016-2301-6 ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 15

Author(s):

Yan Sun ◽

Ying Cheng ◽

Xuezhi Hao ◽

Jie Wang ◽

Chengping Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8016 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8016-8016 ◽

Cited By ~ 7

Author(s):

V. Hirsh ◽

M. Boyer ◽

R. Rosell ◽

R. J. Benner ◽

D. Readett ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

6501 ORAL Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71329-0 ◽

2007 ◽

Vol 5 (4) ◽

pp. 356 ◽

Cited By ~ 1

Author(s):

J. Rolski ◽

T. Grodzki ◽

C.P. Schneider ◽

P. Zatloukal ◽

M. Reck ◽

...

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

A multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdy442 ◽

2018 ◽

Vol 29 ◽

pp. ix121 ◽

Cited By ~ 1

Author(s):

B. Han ◽

K. Li ◽

T. Chu ◽

M. Bi ◽

H. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e318260de75 ◽

2012 ◽

Vol 7 (9) ◽

pp. 1432-1439 ◽

Cited By ~ 25

Author(s):

Thomas H. Fink ◽

Rudolf M. Huber ◽

David F. Heigener ◽

Corrina Eschbach ◽

Cornelius Waller ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Extensive Disease ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

118TiP A multicenter, randomized, double-blind, placebo-controlled phase III trial of camrelizumab plus chemotherapy with or without radiation therapy (RT) as first-line treatment for patients with brain metastatic non-small cell lung cancer (BM-NSCLC; CTONG2003): Trial in progress

Annals of Oncology ◽

10.1016/j.annonc.2021.10.136 ◽

2021 ◽

Vol 32 ◽

pp. S1426-S1427

Author(s):

J. Yang ◽

Y. Pan ◽

F. Ning ◽

L. Lin ◽

X. Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Treatment

Download Full-text

Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8017 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8017-8017 ◽

Cited By ~ 2

Author(s):

C. Manegold ◽

N. Thatcher ◽

R. J. Benner ◽

D. Readett ◽

N. van Zandwijk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%

Annals of Oncology ◽

10.1093/annonc/mdy487.039 ◽

2018 ◽

Vol 29 ◽

pp. x37-x38

Author(s):

V. Sriuranpong ◽

O. Altundag ◽

P. Clingan ◽

N. Rizvi ◽

O. Aren Frontera ◽

...

Keyword(s):

Lung Cancer ◽

Monoclonal Antibody ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdz399 ◽

2019 ◽

Vol 30 (12) ◽

pp. 1978-1984 ◽

Cited By ~ 8

Author(s):

H. Yoshioka ◽

M. Shimokawa ◽

T. Seto ◽

S. Morita ◽

Y. Yatabe ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text